West Pharmaceutical grants CEO options, RSUs

Q: What equity awards did WST grant to President and CEO Michel Lagarde on September 8, 2026?

On September 8, 2026, Michel Lagarde received 37,048 stock options with a $337.75 exercise price and 14,750 restricted stock units, each representing a contingent right to receive one share of West Pharmaceutical common stock.

Q: How do the WST stock option awards to Michel Lagarde vest?

Portions of the option awards vest in four equal annual installments beginning on September 8, 2027, and other portions cliff vest on September 8, 2031, creating a mix of annual and long-term vesting schedules.

Q: How do the WST restricted stock units granted to Michel Lagarde vest?

The 14,750 restricted stock units awarded to Michel Lagarde include units that vest in four equal annual installments starting September 8, 2027 and units that cliff vest on September 8, 2031, with each unit representing one share of common stock.

Q: Are Michel Lagarde’s September 8, 2026 WST equity awards under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the equity awards granted to Michel Lagarde on September 8, 2026.

West Pharmaceutical’s President and CEO received sizable option and restricted stock unit grants with multi‑year vesting and a $337.75 exercise price.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

WEST PHARMACEUTICAL SERVICES INC (WST) reported that its President and CEO, Michel Lagarde, received new equity awards on September 8, 2026. He was granted 37,048 stock options to buy common shares at an exercise price of $337.75 per share, expiring on September 8, 2036. Portions of these option awards vest in four equal annual installments beginning on September 8, 2027, while others cliff vest on September 8, 2031.

Lagarde also received 14,750 restricted stock units, each representing a contingent right to receive one share of WST common stock. Some of these restricted stock units vest annually over four years starting September 8, 2027, and others cliff vest on September 8, 2031. No Rule 10b5-1 trading plan is reported in connection with these awards.

Insider Trade Summary

Grant/Award: 51,798 shares

Grant/Award 6 txns

Insider Lagarde Michel

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	13,879	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) ^F1	11,081	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) ^F2	12,088	$0.00	$0.00
Grant/Award	Rst. Stock Unit ^{F3, F1}	6,200	$0.00	$0.00
Grant/Award	Rst. Stock Unit ^{F3, F1}	4,950	$0.00	$0.00
Grant/Award	Rst. Stock Unit ^{F3, F2}	3,600	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 37,048 contracts (Direct); Rst. Stock Unit — 14,750 contracts (Direct)

Footnotes (3)

F1. This award vests in four equal annual installments beginning on September 8, 2027.
F2. This award cliff vests on September 8, 2031.
F3. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

Key Figures

Stock options granted: 37,048 options Restricted stock units granted: 14,750 units Option exercise price: $337.75 per share +3 more

6 metrics

Stock options granted 37,048 options Granted to President and CEO Michel Lagarde on September 8, 2026

Restricted stock units granted 14,750 units Granted to President and CEO Michel Lagarde on September 8, 2026

Option exercise price $337.75 per share Exercise price for stock options granted on September 8, 2026

Option expiration date September 8, 2036 Expiration for stock options granted to Michel Lagarde

Annual vesting start date September 8, 2027 Start of four equal annual installments for certain awards

Cliff vesting date September 8, 2031 Cliff vesting date for portions of options and restricted stock units

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did WST grant to President and CEO Michel Lagarde on September 8, 2026?

On September 8, 2026, Michel Lagarde received 37,048 stock options with a $337.75 exercise price and 14,750 restricted stock units, each representing a contingent right to receive one share of West Pharmaceutical common stock.

What is the exercise price and expiration date of Michel Lagarde’s new WST stock options?

The stock options granted to Michel Lagarde have an exercise price of $337.75 per share and expire on September 8, 2036, providing a long-dated right to purchase West Pharmaceutical common stock.

How do the WST stock option awards to Michel Lagarde vest?

Portions of the option awards vest in four equal annual installments beginning on September 8, 2027, and other portions cliff vest on September 8, 2031, creating a mix of annual and long-term vesting schedules.

How do the WST restricted stock units granted to Michel Lagarde vest?

The 14,750 restricted stock units awarded to Michel Lagarde include units that vest in four equal annual installments starting September 8, 2027 and units that cliff vest on September 8, 2031, with each unit representing one share of common stock.

Are Michel Lagarde’s September 8, 2026 WST equity awards under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with the equity awards granted to Michel Lagarde on September 8, 2026.

What type of securities underlie Michel Lagarde’s new WST equity awards?

Both the stock options and the restricted stock units are based on West Pharmaceutical common stock. Each restricted stock unit represents a contingent right to receive one share of WST common stock upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/10/2026 - 03:40 PM EDT Accepted by SEC EDGAR 09/10/2026 - 03:40 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lagarde Michel

(Last)

(First)

(Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON

PENNSYLVANIA

19341

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$337.75	09/08/2026		A		13,879		⁽¹⁾	09/08/2036	Common Stock	13,879	$0	13,879	D
Stock Option (Right to Buy)	$337.75	09/08/2026		A		11,081		⁽¹⁾	09/08/2036	Common Stock	11,081	$0	11,081	D
Stock Option (Right to Buy)	$337.75	09/08/2026		A		12,088		⁽²⁾	09/08/2036	Common Stock	12,088	$0	12,088	D
Rst. Stock Unit	⁽³⁾	09/08/2026		A		6,200		⁽¹⁾	⁽¹⁾	Common Stock	6,200	$0	6,200	D
Rst. Stock Unit	⁽³⁾	09/08/2026		A		4,950		⁽¹⁾	⁽¹⁾	Common Stock	4,950	$0	4,950	D
Rst. Stock Unit	⁽³⁾	09/08/2026		A		3,600		⁽²⁾	⁽²⁾	Common Stock	3,600	$0	3,600	D

Explanation of Responses:

1. This award vests in four equal annual installments beginning on September 8, 2027.

2. This award cliff vests on September 8, 2031.

3. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

Remarks:

	/s/ Louis Lalli, as an agent for Michel Lagarde	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR